Key clinical point: A rapid-acting, sustained-release liposomal formulation of dexamethasone for intra-articular injection shows great promise in patients with knee OA.
Major finding: More than half of knee OA patients maintained at least 30% pain relief for 24 weeks after a single intra-articular injection of TLC599, compared with 22% of controls.
Study details: This 24-week, multicenter, placebo-controlled, phase 2a, randomized trial included 75 patients with symptomatic knee OA.
Disclosures: The study was sponsored by the Taiwan Liposome Company. The presenter reported serving as a consultant to that pharmaceutical company and a handful of others.
REPORTING FROM OARSI 2019